29th October
J.N.TATA Auditorium, Indian Institute of Science, Bengaluru.


  • Third largest pharmaceuticals market by 2020 in terms of incremental growth.
  • 20% of global exports in generics, making it the largest provider of generic medicines globally.
  • USD 45 Billion in revenue by 2020, revenue of USD 55 billion by 2020 as base case, and can grow to USD 70 billion in a aggressive case scenario.
  • USD 26.1 Billion in generics by 2016.
  • USD 200 Billion to be spent on infrastructure by 2024.
  • India's filing of Drug Master Files's (DMF's) with USFDA as of Dec 2013 is 3411, the highest filed by any country in the world.
  • Total exports of Drugs, Pharmaceuticals for 2013-14 at USD 15,095 million, recording a growth rate 2.5% over the corresponding period of previous years.

Reasons To Invest

  • India is expected to rank amongst the top three pharmaceutical markets in terms of incremental growth by 2020.
  • India will become the sixth largest market globally in terms of absolute size by zero.
  • India’s generic drugs account for 20% of global exports in terms of volume, making the country the largest provider of generic medicines globally.
  • India’s cost of production is significantly lower than that of the USA and almost half of that of Europe.
  • A skilled workforce as well as high managerial and technical competence.
  • Economic prosperity is likely to improve affordability for generic drugs in the market.
  • Approval time for new facilities has been drastically reduced.


  • The country’s pharmaceuticals industry is expected to account for about 3.1-3.6% of the global pharma industry by value and currently accounts for 10% by volume, by 2016.
  • Industry revenues are expected to expand at a CAGR of 12.1% during 2012-20 and reach USD 45 Billion.
  • The healthcare sector in India is expected to grow to USD 250 Billion by 2020 from USD 65 Billion currently.
  • The generics market is expected to grow to USD 26.1 Billion by 2016 from USD 11.3 Billion in 2011.

Growth Drivers

  • Between 2011 and 2016, patent drugs worth USD 255 Billion are estimated to go off-patent leading to a huge surge in generic product and tremendous opportunities for companies.
  • By 2020, it will grow to USD 11 billion - a CAGR of 18%, with the potential to reach USD 13 billion - at an aggresive CAGR of 20%.
  • With increasing penetration of chemists, especially in rural India, OTC drugs will be readily available.
  • Pharma companies have increased spending to tap rural markets and develop better infrastructure. The market share of hospitals is expected to increase from 13.1% in 2009 to 26% in 2020.
  • Following the introduction of product patents, several multinational companies are expected to launch patented drugs in India.
  • The purported rise of lifestyle diseases in India is expected to boost industry sales figures.
  • Over USD 200 Billion is to be spent on medical infrastructure in the next decade.
  • Rising levels of education are set to increase the acceptability of pharmaceuticals.
  • India’s patient pool is expected to increase to over 20% in the next 10 years, mainly due to the rise in population.


Quick Links

Call for Abstracts
Online Registration
Oral Presentation
Poster Presentation


Journal Publishing Partner.

Branding Partners